This study investigates paediatric drug dosage guidelines with the aim of investigating their agreement with body surface area (BSA) scaling principles.
Introduction
In an ideal world, pharmacokinetic and pharmacodynamic profiles for every paediatric drug would be established and the results would inform dosage guidelines. Unfortunately, for most paediatric drugs these profiles have not been established, leaving a remarkable lack of empirical data to guide dose selection for people under 18 and great variability in quantity and quality of information supporting dose recommendations. Many dosage guidelines rely on the extrapolation of data from adults and animals in conjunction with application of various scaling principles. Often this makes the assumption that children are equivalent to 'small adults' physiologically, physicochemically and biochemically, disregarding the impact of ontogeny on the pharmacokinetics, safety and efficacy of the drugs [1] . Clinicians are aware, however, that development of paediatric drug dosing requires a thorough and rigorous consideration of the effect of developmental changes in medication response, and the large differences in physiological characteristics between children and adults, most notably variation in body composition, differential liver and kidney functioning and drug-metabolizing capacity [2, 3] . It is noteworthy that there are also considerable differences within these parameters across the paediatric age spectrum. For example, some metabolizing enzymes are only a fraction of adult levels during infancy leading to decreased drug clearance and dosing requirements in this age group [4] [5] [6] .
Allometric scaling approaches dosage such that the dose for children is a partial adult dose, dependent on variable factors of age, height and weight [2] . Recommended doses are provided, with paediatricians left to determine a more appropriate dose on a case-by-case basis. Determining doses based on body surface area (BSA; mg m À2 ), is one such favoured allometric scaling approach. BSA can be used as a surrogate for drug metabolism based on the premise that BSA is proportional to heat loss from the body [7] . Furthermore, many other physiological parameters are associated with BSA, such as tissue volume, blood flow and organ size [8] . Dosing based on BSA is not without its limitations. It assumes that adults and children are geometrically similar. While this may be true for children, term and preterm neonates do not have similar morphology to adults; for example, their heads are relatively bigger and body trunks relatively larger. The implication of this is that scaled clearance in infants may be underestimated leading to the underestimation of maintenance dose [9] . Using gestational rather than chronological age may allow optimal dosing that accounts for neonate ontogenesis, although this methodology is not widely adopted and dosage guidelines rarely include preterm newborns. Furthermore, BSA dosing is also prone to errors, because of the complexity of mathematical calculations. Other allometric scaling approaches include the two-thirds power surface area model, using a fixed exponent of 0.67 [1, 10] and the three-quarters power surface area model, using a fixed exponent of 0.75 [11] . Weight-based dosing assumes there is a linear relationship between weight and dose [7] , though drug clearance is better correlated with lean body weight or fat-free weight rather than total body weight [12] and there is currently no bedside method of estimating lean body weight in order to better estimate dose. This is of particular significance in obese children. However, drug dosage guidelines still are often delivered in terms of mg kg À1 or as a set dose, and how well this reflects a desirable BSA scaling method is not immediately evident. Commonly a switch between the dosing regimens (set dose to mg kg À1 or vice versa) will occur at a particular age cutoff somewhere between infancy and childhood, or childhood and adolescence. While these age cutoffs are designed to account for developmental changes in drug metabolism, in the real world the dosing regimen changes seem rather arbitrary and titration between one developmental stage and another is not apparent. Considering paediatric dose recommendations -whether as a set dose or mg kg À1 -in their equivalent weight and height (mg m À2 ) dosage, offers the opportunity to assess the consistency across age groups. Furthermore, when used in children a significant proportion of medications are used on an off-label basis [13, 14] . A 10-week study of a neonatal intensive care unit reported 47% of prescriptions to be off-label [15] . Further, a retrospective study of paediatric inpatients in an Australian teaching hospital reported 31.8% of prescriptions to be off-label [13] and a one-year study including Australian emergency department, inpatient and outpatient clinics at a paediatric teaching hospital reporting off-label use of medications to be around 25.7% [16] . The significant proportion of off-label medication use highlights the need for consistent, evidencebased research to guide dosing regimens in paediatric patients.
In the absence of the pharmacodynamic and pharmacokinetic studies required to inform optimal dosing in children, clinicians rely on national formularies to assist prescribing practices. In Australia, the formulary used for children is the Australian Medicines Handbook Children's Dosing Companion (AMH-CDC) [17] . This resource, like all national formularies, is guided by the best available evidence and undergoes a rigorous editorial and expert review process to formulate its recommendations. Given that the evidence base for dosing simply does not exist for most drugs in children, allometric scaling principles are considered the 'next best' and therefore should be present in dosing guidelines. Using the AMH-CDC, this study investigates dosage guidelines for the paediatric population.
This study aimed to identify various dosage inconsistencies and discontinuities across the age range thereby highlighting the need for research and development of allometric models for paediatric dosing, notwithstanding the priority for complete pharmacokinetic data and established dosing guidelines.
Methods

Data extraction
Information on all 674 dosage guidelines listed in the AMH-CDC 2015 were extracted and collated in Microsoft Excel (2016) . Dosing data extracted from the guide for each drug indication included the administration, frequency and dose per age bracket from birth to 18 years. The average weights and heights for each age group as specified in the AMH-CDC were used. We excluded medications that are not dosed in a way that makes sense to apply dose scaling principles. This includes drugs with the following administration routes: eye, topical, nasal, inhalant, ear, hair, intratracheal, intra-articular. For the same reason we have excluded drugs with no specific regimen. In order to examine dosing guidelines for medications that can be used during most of the paediatric lifespan, we have also excluded medications contraindicated in children under 6 and medications only used in neonates (see Figure 1 for inclusion flowchart).
From the Excel workbook, the included drug treatments were examined in terms of the progression of dosing guidelines from birth until age 18. Based on our observations, the following dosing groups were determined as the best way to categorize the drug dosing patterns across all included medicines:
1. the same dose recommendation for all age or weight groups in milligram/kilogram (mg kg À1 );
2. change in the mg kg À1 dosing according to age or weight;
3. change in the set dose in milligrams (mg) according to age or weight; 4. change from mg kg À1 dosing regimen to a set dose in mg according to age or weight; 5. the same dose recommendation for all age or weight groups in mg; or 6. drugs dosed according to BSA (mg m À2 ).
To ensure that these dosing categories were not only a reflection of Australian guidelines, the British National Formulary (BNF) for Children [18] was also checked. For each included drug in the CDC we searched the drug recommendations in the BNF when indicated for the same or equivalent indication, administration route and formulation. The BNF doses for these drugs were then examined and categorized according to the same dosing groups determined for the CDC. 
Disruptions in recommended drug dosages for children
In the current analysis we have used BSA as an example allometric scaling principle. BSA makes similar adjustments to the dose as other scaling principles such as exponent 0.75 and 0.67. This similarity is demonstrated in Figure 2 . To illustrate differences in BSA across the paediatric lifespan, we arbitrarily selected example drugs from the CDC from dose group categories 1-4. Category 5 was not graphed as these drugs did not change dose recommendation according to age or weight and category 6 was not graphed as it includes medications already dosed according to BSA. For each selected drug the minimum and maximum dosage in mg, mg kg À1 and the equivalent, milligrams per body surface area (mg m À2 ) for each age group was calculated using the average weights and heights per age bracket provided in the AMH-CDC. Body surface area was calculated using the Mosteller formula as follows:
The minimum and maximum mg kg À1 doses were then converted to GraphPad Prism Version 6 for Windows (GraphPad Software, La Jolla, CA, USA), where graphs were plotted, providing a function to observe the trends progressing through age (birth to 17), average weight (3.3-62 kg) and average height (50-160 cm). Discontinuities were defined as a disruption in mg m À2 dosage across age groups as a result of change in dose from mg kg À1 to a set dose or vice versa. As well as cross-referencing to the BNF, the selected drugs were also compared to the American Hospital Formulary Service (AHFS) [19] to assess the international similarities and differences in dosing recommendations.
Nomenclature of ligands
Key ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHAR-MACOLOGY [20] , or the PubChem database https://www. ncbi.nlm.nih.gov/pccompound.
Results
There were 465 drug treatments included in the study. Close to two-thirds of the drug treatments (n = 289, 63%) had the same dose mg kg À1 for all age and weight groups (dose category 1), 14% (n = 65) of drug treatments were dosed in mg kg À1 across all ages but the dose changed one or more times according to changes in weight or age (dose category 2), 13% (n = 61) of drug treatments were dosed in mg across all ages but the set dose changed one or more times according to changes in weight or age (dose category 3), 10% (n = 48) of drug treatments switched from dosing according to mg kg À1 to a set dose in mg according to changes in weight or age (dose category 4), 4.2% (n = 19) had the same dose in mg for all age and weight groups and the remaining 2.2% (n = 10) were dosed according to BSA. All included CDC drug treatments and their dose group categories are shown in Supporting Information Data S1. Of the 454 included drug treatments from the CDC, 325 were also present in the BNF with equivalent administration routes, formulations and indications. Over a third of those (n = 126, 38.8%) fit into dose category 1, 14.1% (n = 46) in dose category 2, 12.6% (n = 41) in dose category 3, 27.4% (n = 89) in dose category 4, 3.7% (n = 12) in dose category 5 and the remaining 3.4% in dose category 6. Figure 5 , desmopressin, is an example from dosing category 3. The stepwise increase in recommended mg/age can be seen in the figure, with a range introduced at age 12. Maximum dose recommendation for desmopressin in the BNF is higher for all age categories, whereas the AHFS recommends a fixed dose; however, individualized dosing according to needs is advocated. Figures 6-9 are examples from dosing category 4. Oseltamivir ( Figure 6) fluctuates within the range 100-138 mg m À2 from birth to 15, before steadily dropping to 87.8 mg m À2 at age 17. Cefuroxime (Figure 7) shows an abrupt increase in mg m À2 at age 2 before dropping steadily back to the starting dose at age 12, where ranges are then introduced. Dosing recommendations for both oseltamivir and cefuroxime are similar between the AMH-CDC, BNF and AHFS. Voriconazole (Figure 8 ) linearly increases from 400 mg m À2 at age 2 to~550 mg m À2 at age 11, before decreasing slightly before a range is introduced. Vigabatrin ( Figure 9 ) shows wide ranges from birth equivalent tõ 2000 mg m À2 differences between the minimum and 
Discussion
This study aimed to investigate paediatric dosing recommendations in terms of their adherence to the BSA scaling principle and the associated inconsistencies or sudden dose transitions across age groups. The illustrated drug treatments chosen from the AMH-CDC had dose recommendations that were overall similar to recommendations provided by the BNF for Children and the AHFS. The drugs showed various dosage patterns, some associated with dose disruptions or Shaded areas indicate the range for minimum and maximum dose. Equivalent doses calculated from the recommended dose based on average weight or body surface area per age group discontinuities across the paediatric age range. Those that allow for quite consistent dosing across the age range are those with large dose ranges, though in some cases having such broad therapeutic recommendations can be unhelpful in terms of prescribing individualized treatment. With a lack of appropriate pharmacodynamic and pharmacokinetic studies to guide more accurate dosing, we considered current dosage guidelines that allow similar physiological concentrations between birth to age 18 (as reflected in the equivalent mg m À2 graph) as the next best. It is noteworthy that only around 2% of drugs in the CDC and 3.4% of the equivalent drugs in the BNF were dosed according to BSA, although drugs commonly dosed according to BSA such as chemotherapy agents are not commonly listed in the CDC as they are protocol specific. From the illustrated drug treatments, the BSA equivalent doses for oseltamivir, dexamethasone and vigabatrin best demonstrate opportunity for fairly consistent dosing across children of different age groups. Dexamethasone is dosed at a constant mg kg À1 which corresponds to a BSA dosage which increases greater than twofold between birth to age 18, the acceptable range of dosing would allow fairly consistent mg m À2 dosing throughout the age range ( Figure 3 ). Likewise, vigabatrin shows a drug with wide ranges from birth which allow consistent mg m À2 dosing; however, its minimum and maximum doses display inconsistent patterns (Figure 9 ).
Known pharmacokinetic data of vigabatrin (Sabril, Sanofi Aventis) in the paediatric population report a comparison of neonates (age 15-26 days), infants (age 5-22 months) and children (age 4.6-14.2 years), showing decreased clearance with age groups, but similar renal clearance in children to adults [21] . In an early clinical trial, 66 children aged between 2 and 15 treated with vigabatrin found optimal efficacy between 40 and 80 mg kg À1 day
À1
, with doses over 100 mg kg À1 day À1 resulting in no significant adverse events [22] , supporting the wide therapeutic window reflected in vigabatrin dosing guidelines. Pharmacokinetic modelling of oseltamivir has indicated that in children 1-12 years, a dose of 2 mg kg À1 results in a cumulative dose similar to that which is safe and effective in adults [23] . A randomized controlled trial showed this dosage was well-tolerated and had efficacy for influenza [23] , though this is not the recommended dosage in the AMH-CDC ( Figure 6 ). Digoxin is an example drug treatment with a very narrow therapeutic range. As can be seen in Figure 4 , there is much less variability in the BSA dose than the mg kg À1 dose, highlighting the strength of this approach. Yet fixed dosing according to a fixed mg kg À1 remains the dominant recommendation. For other treatments, ranges are available but not until age 12; for example, desmopressin ( Figure 5 ) and cefuroxime ( Figure 7) , which display very similar BSA The greatest discontinuities we observed were a result of a switch in dosing guidelines between a set dose or a dose based on weight, which commonly occurred between ages 12 and 14. The Center for Drug Evaluation and Research generally categorizes paediatric age groups into: neonates (birth to one month); infants (1 month to two years); children (2-12 years) and adolescents (12) (13) (14) (15) (16) . Though in their working guidance for industry document, the Food and Drug Administration recognizes these specific age groups do not necessarily need to be used in studies but alternative age groupings based on physiology should be scientifically supported [24] . In the case of weight-based dosing, there is less variability during infancy and childhood until about the age of 13 when the variation of age with weight is highest [25] , which reflects the dosing switches seen across drugs in this study.
Commonly what is seen is dose recommendations based on available drug formulations. For example, cefuroxime, one of the example drug treatments with the most inconsistent and disrupted BSA equivalent dosing, is one in which the recommendations align with exact multiples of the tablet formulation (250 mg). On the other side of the coin, how well clinicians are able to meet the recommended oral dosing guidelines is based on the available formulations of the drug. For example, treating a typical~9 kg 1-year-old child for central diabetes insipidus with desmopressin ( Figure 5 ) according to oral dose recommendations requires 10 μg of the medication twice or three times daily, yet the medication is only available in tablet formulations of 200 μg. Further, the guidelines commonly provided dosages in simple weight-based formulas, which are less complicated and as such less prone to error than those prescribed according to BSA. However, current technology does enable electronic calculation to decrease the risk of error.
The implications of the inconsistent and discontinuous drug recommendations identified in our investigation are more important for some drugs than others. For example, continuing medications such as pamidronate, digoxin and vigabatrin require a much greater dosing consistency across age groups compared to medications with a shorter course length, such as those for infections. That said, it is important to consider that a 13-year-old adolescent with a serious fungal infection would be recommended a voriconazole dose of 480 mg m À2 and a child one year older could receive a dose as low as 265 mg m À2 . It is unknown how, on the population level, these discontinuous recommendations are treated clinically. An analysis of prescribing data would be very useful in that sense, in order to utilize real-world data to further guide dose recommendations. Dose finding studies in children are difficult [7] . Therefore, many drugs used in children do not have paediatric labelling information [26] . Formularies can be improved by utilizing model-based methods to determine optimal paediatric dosage of existing drugs. For example, paediatric models have been successfully developed for various drugs including midazolam, lorazepam, tramadol, acetaminophen and voriconazole [27] . In several countries, new drug development for children requires paediatric investigation plans [28, 29] and modelbased methods for dose optimization are required [30] . Interest in model-based methods for personalized medicine is increasing, particularly for genotype-directed therapy [31] . Furthermore, physiology-based pharmacokinetic models have been used to evaluate drugs for potential drug-drug interactions [32] . Thus, the effect of various dosing regimens on interacting drugs can be established and drugs can be individually optimized for polytherapy [33] .
Conclusion
Paediatric dosage guidelines appear to be based on simple formulas (such as mg kg À1 ), available dosing formulations and prior patterns of use. Two or more-fold variation from doses that would be predicted by allometric scaling are common, as are arbitrarily large shifts in recommended doses at age thresholds. While doses may be safely approximated for drugs with large therapeutic margins, accurate dose estimation for drugs with narrow therapeutic margin is imperative in order to minimize the risk of drug toxicity. Drugs used to treat childhood leukaemia are routinely dosed using BSA [34, 35] , which has contributed to achieving impressive improvement in outcomes in recent years [35] .
In the absence of pharmacokinetic and pharmacodynamic studies, further research is required to determine whether better outcomes could be achieved in paediatric conditions by adopting biologically based scaling of paediatric doses.
